PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy-Reference-Cited by-同舟云学术

PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy

Published:2019-01 Issue:1 Volume:201 Page:91-97
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Faiena Izak¹,Salmasi Amirali¹,Mendhiratta Neil¹,Markovic Daniela²,Ahuja Preeti³,Hsu William³,Elashoff David A.²,Raman Steven S.¹³,Reiter Robert E.¹⁴

Affiliation:

1. Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California

2. Department of Medicine Statistics Core, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California

3. Department of Radiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California

4. Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A deep learning model, NAFNet, predicts adverse pathology and recurrence in prostate cancer using MRIs;npj Precision Oncology;2023-12-11

2. Nanoribbon Biosensor-Based Detection of microRNA Markers of Prostate Cancer;Sensors;2023-08-30

3. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study;World Journal of Urology;2023-07-07

4. Air data computer simulation and design credibility assessment considering ADC calculation model;Applied Mathematics and Nonlinear Sciences;2023-04-28

5. The Value of the Prostate Health Index and Derived Indexes in the Diagnosis of Prostate Cancer with PI-RADS-3 Lesions;Urologia Internationalis;2023